Frustrations from pharma companies and the NHS toward NICE have been reported on since NICE was introduced in 1999, and as the governing body for quality standards and cost-benefit assessment for new treatments in the UK, the relationship is essential to ensuring patient access throughout the country. NICE have recently committed to reviewing some of their guidelines and ens...